Chronic Obstructive Pulmonary Disease (COPD) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025
Chronic
Obstructive Pulmonary Disease (COPD) Emerging Therapy and TPP Insights
Thelansis’s “Chronic
Obstructive Pulmonary Disease (COPD) Emerging Therapy, with Unmet Needs and TPP
Insights Report – 2025″ provides a comprehensive analysis of the emerging
competitive landscape, unmet needs, target product profiles (TPPs), trial
designs, and KOL insights on key emerging therapies and key drug development
opportunities in the indication.
Chronic
Obstructive Pulmonary Disease (COPD) Overview
Chronic
Obstructive Pulmonary Disease (COPD) is a significant global contributor to
chronic illness and premature death. As the third leading cause of death
worldwide, its prevalence and fatality rates are projected to rise in the
coming decades. The disease is characterized by chronic inflammation that
causes structural alterations and constriction in the smaller air passages.
This inflammatory process also drives lung tissue damage, resulting in the
detachment of alveoli from smaller airways and a decrease in lung elasticity,
which ultimately reduces the airways’ ability to remain open during exhalation.
To assess the extent of airflow restriction, spirometry serves as the most
accessible and dependable measure of lung function, with diagnosis confirmed by
a post-bronchodilator FEV1/FVC ratio of less than 0.70. The clinical impact of
COPD on an individual is determined not only by the degree of airflow
limitation but also by the severity of associated symptoms and the frequency of
exacerbations. Because an imperfect correlation exists between the degree of
airflow limitation and patient symptoms, modern staging acts as a practical
framework that combines spirometric grading with symptom burden and
exacerbation risk to guide the initial management plan.
Geography
coverage:
G8 (United
States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights
driven by surveys* with physician / key opinion leaders:
- Survey findings are corroborated and
enriched by insights from interviews with leading KOLs
*Survey is
customized based on client requirements
Deliverables
format:
- PowerPoint presentation
- MS Excel
Key business
questions answered:
- Detailed emerging competitive
landscape
- Pipeline
analysis
- Target patients
for emerging therapies
- Key companies
- Key mechanism of
actions
- Launch date
estimates, etc.
- Clinical trial landscape analysis
- Target patient
segments
- Trial endpoints
- Trial design
- Recruitment
criteria, etc.
- Unmet Needs and Opportunities
- Performance of
key current therapies
- Top areas of
unmet needs
- Opportunity
sizing for key unmet needs
- Target Product Profiles
- Attributes and
levels
- Physician
likelihood of prescribing
- Expected patient
shares
- KOL insights on key emerging
therapies
- Level of
awareness
- Expected use /
line of therapy
- Extent to fulfil
key unmet needs
- KOL quotes
Comments
Post a Comment